Trial record 1 of 1 for:    mcl4001
Previous Study | Return to List | Next Study

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Pharmacyclics
Information provided by (Responsible Party):
Janssen Biotech, Inc.
ClinicalTrials.gov Identifier:
NCT01833039
First received: April 6, 2013
Last updated: July 3, 2014
Last verified: July 2014
  Purpose

The purpose of this study is to provide patients who have relapsed or refractory Mantle Cell Lymphoma (MCL) with early access to an investigational medication called ibrutinib (PCI-32765) and to collect safety information about the drug.


Condition Intervention Phase
Relapsed or Refractory Mantle Cell Lymphoma
Drug: Ibrutinib
Phase 4

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: An Open-Label Treatment Use Protocol for Ibrutinib (PCI-32765) in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Resource links provided by NLM:


Further study details as provided by Janssen Biotech, Inc.:

Primary Outcome Measures:
  • Percentage of Patients With Treatment Emergent Adverse Experiences during the study. [ Time Frame: Start of study drug to 30 Days post study drug administration ] [ Designated as safety issue: Yes ]
    Percentage of Patients With Treatment Emergent Adverse Experiences during the study.


Enrollment: 150
Study Start Date: May 2013
Estimated Study Completion Date: May 2016
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ibrutinib
Ibrutinib
Drug: Ibrutinib
Ibrutinib

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients, 18 years of age and older, with Mantle Cell Lymphoma who have relapsed or refractory disease after prior therapy are eligible.

Exclusion Criteria:

  • Patients eligible for enrollment in any other ongoing clinical study of ibrutinib are not eligible.
  • Patients previously treated with ibrutinib are not eligible.
  • Patients enrolled in another interventional clinical study with therapeutic intent are not eligible.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01833039

  Hide Study Locations
Locations
United States, Arizona
Phoenix, Arizona, United States
United States, California
Duarte, California, United States
Los Angeles, California, United States
Stanford, California, United States
United States, Colorado
Denver, Colorado, United States
United States, Connecticut
Norwalk, Connecticut, United States
Stamford, Connecticut, United States
United States, District of Columbia
Washington, District of Columbia, United States
United States, Florida
Miami Beach, Florida, United States
Ocala, Florida, United States
Orlando, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Illinois
Chicago, Illinois, United States
Springfield, Illinois, United States
United States, Indiana
Goshen, Indiana, United States
United States, Iowa
Sioux City, Iowa, United States
United States, Kentucky
Lexington, Kentucky, United States
Louisville, Kentucky, United States
United States, Louisiana
Metairie, Louisiana, United States
United States, Maryland
Baltimore, Maryland, United States
United States, Massachusetts
Boston, Massachusetts, United States
Worcester, Massachusetts, United States
United States, Michigan
Detroit, Michigan, United States
United States, Minnesota
Rochester, Minnesota, United States
United States, Missouri
Jefferson City, Missouri, United States
St. Louis, Missouri, United States
United States, Nebraska
Lincoln, Nebraska, United States
Omaha, Nebraska, United States
United States, Nevada
Reno, Nevada, United States
United States, New Jersey
Hackensack, New Jersey, United States
United States, New York
New Hyde Park, New York, United States
New York, New York, United States
Syracuse, New York, United States
United States, Ohio
Cleveland, Ohio, United States
Columbus, Ohio, United States
United States, Pennsylvania
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
United States, South Dakota
Watertown, South Dakota, United States
United States, Tennessee
Knocksville, Tennessee, United States
United States, Texas
Austin, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
United States, Vermont
Burlington, Vermont, United States
United States, Virginia
Charlottesville, Virginia, United States
United States, West Virginia
Morgantown, West Virginia, United States
Puerto Rico
San Juan, Puerto Rico
Sponsors and Collaborators
Janssen Biotech, Inc.
Pharmacyclics
  More Information

No publications provided

Responsible Party: Janssen Biotech, Inc.
ClinicalTrials.gov Identifier: NCT01833039     History of Changes
Other Study ID Numbers: CR101862, PCI-32765MCL4001
Study First Received: April 6, 2013
Last Updated: July 3, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by Janssen Biotech, Inc.:
Mantle Cell Lymphoma
Ibrutinib

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin

ClinicalTrials.gov processed this record on August 18, 2014